Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharmaceuticals limited - lisinopril dihydrate - oral solution - 1 mg/ml - lisinopril - angiotensin-converting enzyme inhibitors - treatment of hypertension; treatment of symptomatic heart failure; treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction; treatment of renal disease in hypertensive patients with type 2 diabetes mellitus and incipient nephropathy

Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharma ltd - calcitonin, salmon - solution for injection/infusion - 100 international unit(s)/millilitre - calcitonin preparations; calcitonin (salmon synthetic)

Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharma ltd - calcitonin, salmon - solution for inj/inf - 50 iu/ml - calcitonin (salmon synthetic)

Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharma ltd - potassium chloride - tablet prolonged release - 600 milligram - potassium chloride

European Union - English - EMA (European Medicines Agency)

crealta pharmaceuticals ireland limited - pegloticase - gout - antigout preparations - krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

European Union - English - EMA (European Medicines Agency)

jenson pharmaceutical services limited - dextromethorphan, quinidine - neurobehavioral manifestations - other nervous system drugs - nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (pba) in adults. efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.

European Union - English - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

European Union - English - EMA (European Medicines Agency)

teva b.v. - telmisartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.

European Union - English - EMA (European Medicines Agency)

nps pharma holdings limited - parathyroid hormone (rdna) - osteoporosis, postmenopausal - calcium homeostasis - treatment of osteoporosis in postmenopausal women at high risk of fractures (see section 5.1).a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

European Union - English - EMA (European Medicines Agency)

teva b.v. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. treatment of paget’s disease of the bone in adults.,